Incisive Surgical Inc.
This article was originally published in Start Up
Incisive Surgical was founded because of a plastic surgeon's frustration with existing methods of closing incisions. While sutures achieve the best cosmetic result, they consume a lot of expensive operating room time. Staples are fast, but scar tissue at a greater rate than sutures. With an absorbable subcuticular stapling system, Incisive hopes to combine the cosmetic results of sutures with the speed of staples.
You may also be interested in...
For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (A Reprint of "Advanced Wound Care: The Device Industry's Billion Dollar Product Market," appearing in START-UP, November 2007.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.